Gastric Cancer | Clinical

Europe Joins US in Approval of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

December 19, 2022

Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

PD-L1 CPS Plays Role in Selecting Treatment for Gastric Cancer

December 09, 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.

Managing Adverse Events of Nivolumab/Chemotherapy for Gastric/GEJ Cancers

November 18, 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.